nature portfolio

Jiangtao Zhou; Roland Rick;

Corresponding author(s): Raffaele Mezzenga

Last updated by author(s): Sep 6, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

$\overline{}$					
Š	†:	† د	ıc	ŀι	CS
.)		11	ירו		1

n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
,	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection Nanoscope 8.1 (Bruker, USA); EPU (Thermo Fisher Scientific); TopSpin 3.6 (Bruker)

Data analysis Excel; Origin Pro; FiberAPP; Easyworm; RELION 4.0; Ctffind 4.1; ModelAngelo; COOT; CCP4MG; UCSF Chimera; STRIDE; SHIFTX2; FLYA

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The data used to reproduce the results are available within the article, Supplementary Information file and the Source Data file. The custom script used to simulate ssNMR 2D DARR spectra is available upon request by contacting the leading author. All other software utilized in this study are open-source packages. The coordinates for the hen egg white and human lysozyme fibril models have been deposited in the PDB with accession codes 8QV8 and 8QUT, respectively. Likewise, the Cryo-EM maps for hen egg white and human lysozyme fibrils have been deposited in the EMDB with accession codes 18669 and 18663, respectively.

Research involving human participants, their data, or biological material				
Policy information	about studies w	vith <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation), thnicity and racism</u> .		
Reporting on sex and gender		n/a		
Reporting on race, ethnicity, or other socially relevant groupings		n/a		
Population characteristics		n/a		
Recruitment		n/a		
Ethics oversight		n/a		
Note that full informa	ation on the appr	oval of the study protocol must also be provided in the manuscript.		
Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
Life sciences	В	ehavioural & social sciences		
For a reference copy of	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life sciences study design				
All studies must dis	sclose on these	points even when the disclosure is negative.		
Sample size	The study of bo	th reversible and irreversible fibril formation was performed in more than five independent experiment.		
Data exclusions	No data was excluded.			
Replication	Following the description in the method section			
Randomization	n/a			
Blinding	n/a			
Reporting for specific materials, systems and methods				
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.				
Materials & experimental systems Methods				

Materials & experimental systems		Methods		
n/a	Involved in the study	n/a	Involved in the study	
\boxtimes	Antibodies	\boxtimes	ChIP-seq	
\boxtimes	Eukaryotic cell lines	\boxtimes	Flow cytometry	
\boxtimes	Palaeontology and archaeology	\boxtimes	MRI-based neuroimaging	
\boxtimes	Animals and other organisms			
\boxtimes	Clinical data			
\boxtimes	Dual use research of concern			
\boxtimes	Plants			

Plants

Seed stocks	n/a
Novel plant genotypes	n/a
Authentication	n/a